The top medtech stories of early 2017

Share
Abbott Laboratories catheter-delivered bioresorbable Absorb stent.

Abbott Laboratories’s bioresorbable Absorb stent.

FDA warning about Abbott’s Absorb stent

Abbott Labs’s Absorb bioresorbable stent was one of the most promising medical devices that FDA approved last year. Now, there is a cloud over the stent’s potential after FDA this month issued a warning to physicians.

FDA issued the warning after new study data that showed that Absorb had a higher risk of serious adverse events at 2 years compared with the company’s Xience drug-eluting stent. Nearly a fifth of the 2,008 patients in the study, however, had stents implanted in arteries that are now considered too small for the device. Exclude the patients with the too-small arteries, and there was no statistical significance between Absorb and Xience in the study.

Next>>

DeviceTalks West: Expertise you need to know

textadimage Medical device suppliers are light years away from the days when they merely filled orders to spec for medtech OEMs – as a visit to the upcoming DeviceTalks West will quickly confirm.

From incorporating steerability into catheters to getting validation and testing done right, the companies serving the medical device industry have become specialized experts in their own right.

Read on to discover five example of medical device expertise to be had at DeviceTalks West, which runs Dec. 11–12 in Orange County, Calif.

Pages: 1 2 3 4 5 6

Speak Your Mind

*